SCHEMBL3602906

SCHEMBL3602906

COc1ccc(-c2csc(NC(=N)N)n2)cc1CN

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.58
KMT2A Q03164 10/20 0.58
MAPK1 P28482 2/20 0.58
ALDH1A1 P00352 2/20 0.58
ALOX15 P16050 1/20 0.58
HSD17B10 Q99714 1/20 0.58
POLB P06746 3/20 0.52
HPGD P15428 1/20 0.50
RAB9A P51151 2/20 0.49
PAX8 Q06710 1/20 0.48
KDM4E B2RXH2 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
GPR65 Q8IYL9 1/20 0.46
MCL1 Q07820 1/20 0.46
ROCK2 O75116 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597000 0.88 MEN1 (0.73) MEN1KMT2AMAPK1ALDH1A1ALOX15
SCHEMBL3593888 0.85 MEN1 (0.63) MEN1KMT2AMAPK1ALDH1A1ALOX15
SCHEMBL3604738 0.85 MEN1 (0.61) MEN1KMT2AMAPK1ALDH1A1ALOX15
SCHEMBL27768262 0.81 ABL1 (0.43) MEN1KMT2AMAPK1ALDH1A1ALOX15
SCHEMBL3593375 0.79 MEN1 (0.57) MEN1KMT2AMAPK1ALDH1A1ALOX15
SCHEMBL3608324 0.78 MEN1 (0.57) MEN1KMT2AMAPK1ALDH1A1ALOX15
SCHEMBL3595657 0.78 PTGS2 (0.66) MEN1KMT2AMAPK1ALDH1A1POLB
SCHEMBL8650286 0.77 ATP4A (0.62) RAB9ANPC1MAPT
SCHEMBL27768308 0.76 AOC3 (0.50) MEN1KMT2AALDH1A1ALOX15HSD17B10
SCHEMBL3613302 0.76 ALDH1A1 (0.72) MEN1KMT2AALDH1A1HSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 MEN1 3257/4885KMT2A 4116/4885MAPK1 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.